As US, China Intensify Cybersecurity Crackdown, Companies Urged To Be Conservative
Vague Definitions, Increasing Uncertainty
The latest developments around data security and protection signal the need for rigorous implementation of procedures and potential significant cost increases for pharma and other companies operating in China.
You may also be interested in...
Beijing imposes $1.2bn in fines on China's largest ride-hailing operator Didi for personal data security violations, putting the spotlight once again on the need to pay close attention to the latest draft regulations in the area, which could have a profound impact on any foreign businesses - including pharma - operating in the world’s second-largest economy.
Big data player and “Flatiron of China” is putting off its plans to go public amid regulatory scrutiny over DiDi and other companies listed in the US, but biotech firms need to worry less, says one investor.
Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.